{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:09:58Z","timestamp":1791266998799,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82160859"],"award-info":[{"award-number":["82160859"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018622","name":"Program for Top 100 Innovative Talents in Colleges and Universities of Hebei Province","doi-asserted-by":"publisher","award":["--"],"award-info":[{"award-number":["--"]}],"id":[{"id":"10.13039\/501100018622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40256-024-00709-6","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T16:13:18Z","timestamp":1734538398000},"page":"373-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cardiovascular Events Associated with CDK4\/6 Inhibitors: A Safety Meta-Analysis of Randomized Controlled Trials and a Pharmacovigilance Study of the FAERS Database"],"prefix":"10.1007","volume":"25","author":[{"given":"Chengrong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoshuang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YongXin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhoujuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanzhen","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1266-8943","authenticated-orcid":false,"given":"Jiuda","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"709_CR1","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1038\/s41467-024-47002-3","volume":"15","author":"E Dumas","year":"2024","unstructured":"Dumas E, Grandal Rejo B, Gougis P, Houzard S, Ab\u00e9cassis J, Jochum F, et al. Concomitant medication, comorbidity and survival in patients with breast cancer. Nat Commun. 2024;15:2966.","journal-title":"Nat Commun"},{"key":"709_CR2","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/jnci\/djq409","volume":"102","author":"L Bonilla","year":"2010","unstructured":"Bonilla L, Ben-Aharon I, Vidal L, Gafter-Gvili A, Leibovici L, Stemmer SM. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2010;102:1845\u201354.","journal-title":"J Natl Cancer Inst"},{"key":"709_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372.","journal-title":"Lancet"},{"key":"709_CR4","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","volume":"40","author":"KM Sturgeon","year":"2019","unstructured":"Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40:3889\u201397.","journal-title":"Eur Heart J"},{"key":"709_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115373","volume":"166","author":"C Liu","year":"2023","unstructured":"Liu C, Chen H, Guo S, Liu Q, Chen Z, Huang H, et al. Anti-breast cancer-induced cardiomyopathy: mechanisms and future directions. Biomed Pharmacother. 2023;166: 115373.","journal-title":"Biomed Pharmacother"},{"key":"709_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/annonc\/mdw604","volume":"28","author":"NG Zaorsky","year":"2017","unstructured":"Zaorsky NG, Churilla TM, Egleston BL, Fisher SG, Ridge JA, Horwitz EM, et al. Causes of death among cancer patients. Ann Oncol. 2017;28:400\u20137.","journal-title":"Ann Oncol"},{"key":"709_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.canep.2016.06.013","volume":"44","author":"DC Whiteman","year":"2016","unstructured":"Whiteman DC, Wilson LF. The fractions of cancer attributable to modifiable factors: a global review. Cancer Epidemiol. 2016;44:203\u201321.","journal-title":"Cancer Epidemiol"},{"key":"709_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029361","volume":"12","author":"MG Fradley","year":"2023","unstructured":"Fradley MG, Nguyen NHK, Madnick D, Chen Y, DeMichele A, Makhlin I, et al. Adverse cardiovascular events associated with cyclin-dependent kinase 4\/6 inhibitors in patients with metastatic breast cancer. J Am Heart Assoc. 2023;12: e029361.","journal-title":"J Am Heart Assoc"},{"key":"709_CR9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1080\/14740338.2017.1351541","volume":"16","author":"S Martel","year":"2017","unstructured":"Martel S, Maurer C, Lambertini M, Pond\u00e9 N, De Azambuja E. Breast cancer treatment-induced cardiotoxicity. Expert Opin Drug Saf. 2017;16:1021\u201338.","journal-title":"Expert Opin Drug Saf"},{"key":"709_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072924","volume":"380","author":"MP Little","year":"2023","unstructured":"Little MP, Azizova TV, Richardson DB, Tapio S, Bernier M-O, Kreuzer M, et al. Ionising radiation and cardiovascular disease: systematic review and meta-analysis. BMJ. 2023;380: e072924.","journal-title":"BMJ"},{"key":"709_CR11","unstructured":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)\u2014PubMed [Internet]. [cited 2023 Sep 3]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36017568\/."},{"key":"709_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.143","volume":"3","author":"B Liu","year":"2024","unstructured":"Liu B, Hu Z-Y, Xie N, Liu L, Li J, Yang X, et al. Beyond clinical trials: CDK4\/6 inhibitor efficacy predictors and nomogram model from real-world evidence in metastatic breast cancer. Cancer Innov. 2024;3: e143.","journal-title":"Cancer Innov."},{"key":"709_CR13","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","volume":"27","author":"B Xu","year":"2021","unstructured":"Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021;27:1904\u20139.","journal-title":"Nat Med"},{"key":"709_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JGO.19.11000","volume":"5","author":"S-A Im","year":"2019","unstructured":"Im S-A, Mukai H, Park IH, Masuda N, Shimizu C, Kim S-B, et al. Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study. J Glob Oncol. 2019;5:1\u201319.","journal-title":"J Glob Oncol."},{"key":"709_CR15","doi-asserted-by":"publisher","first-page":"175883592311518","DOI":"10.1177\/17588359231151840","volume":"15","author":"S Paluch-Shimon","year":"2023","unstructured":"Paluch-Shimon S, Neven P, Huober J, Cicin I, Goetz MP, Shimizu C, et al. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2\u2212, node-positive, high-risk early breast cancer. Ther Adv Med Oncol. 2023;15:17588359231151840.","journal-title":"Ther Adv Med Oncol."},{"key":"709_CR16","doi-asserted-by":"publisher","unstructured":"NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor\u2013positive (HR+), human epidermal growth factor receptor 2-negative (HER2\u2013) early breast cancer (EBC). J Clin Oncol [Internet]. [cited 2024 Jan 22]. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS597.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS597"},{"key":"709_CR17","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2022.1488","volume":"8","author":"M Martin","year":"2022","unstructured":"Martin M, Hegg R, Kim S-B, Schenker M, Grecea D, Garcia-Saenz JA, et al. Treatment with adjuvant abemaciclib plus endocrine therapy in patients with high-risk early breast cancer who received neoadjuvant chemotherapy: a prespecified analysis of the monarchE randomized clinical trial. JAMA Oncol. 2022;8:1190\u20134.","journal-title":"JAMA Oncol"},{"key":"709_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2217\/fon-2021-0716","volume":"18","author":"K Mycock","year":"2022","unstructured":"Mycock K, Zhan L, Hart K, Taylor-Stokes G, Milligan G, Atkinson C, et al. Real-world treatment of patients with palbociclib for HR+\/HER2\u2212 advanced\/metastatic breast cancer: the Europe IRIS study. Future Oncol. 2022;18:349\u201362.","journal-title":"Future Oncol"},{"key":"709_CR19","doi-asserted-by":"publisher","first-page":"175883592312058","DOI":"10.1177\/17588359231205848","volume":"15","author":"D Pavlovic","year":"2023","unstructured":"Pavlovic D, Niciforovic D, Papic D, Milojevic K, Markovic M. CDK4\/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity\u2014a narrative review. Ther Adv Med Oncol. 2023;15:17588359231205848.","journal-title":"Ther Adv Med Oncol."},{"key":"709_CR20","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904\u201315.","journal-title":"Lancet Oncol"},{"key":"709_CR21","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im S-A, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465\u201372.","journal-title":"J Clin Oncol"},{"key":"709_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10549-017-4523-y","volume":"167","author":"GS Sonke","year":"2018","unstructured":"Sonke GS, Hart LL, Campone M, Erdkamp F, Janni W, Verma S, et al. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat. 2018;167:659\u201369.","journal-title":"Breast Cancer Res Treat"},{"key":"709_CR23","unstructured":"Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer\u2014the Penelope-B trial\u2014PubMed [Internet]. [cited 2024 Nov 8]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33793299\/."},{"key":"709_CR24","unstructured":"Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03)\u2014PubMed [Internet]. [cited 2024 Nov 8]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34874182\/."},{"key":"709_CR25","unstructured":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial\u2014PubMed [Internet]. [cited 2023 Jun 12]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26947331\/."},{"key":"709_CR26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","volume":"24","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang Q, Tong Z, Sun T, Li W, Ouyang Q, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023;24:646\u201357.","journal-title":"Lancet Oncol"},{"key":"709_CR27","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1002\/onco.13531","volume":"26","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Huober J, Garc\u00eda-S\u00e1enz JA, Masuda N, Sohn JH, Andre VAM, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist. 2021;26:e53-65.","journal-title":"Oncologist"},{"key":"709_CR28","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638\u201346.","journal-title":"J Clin Oncol"},{"key":"709_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx365.086","volume":"28","author":"MM Jimenez","year":"2017","unstructured":"Jimenez MM, Bachelot T, Barrios C, Blackwell K, Chia S, Laurentiis MD, et al. EarLEE-1: a phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2\u2013), high-risk, early breast cancer (EBC). Ann Oncol. 2017;28: v107.","journal-title":"Ann Oncol"},{"key":"709_CR30","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol. 2023;41:4004\u201313.","journal-title":"J Clin Oncol"},{"key":"709_CR31","unstructured":"Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study\u2014PubMed [Internet]. [cited 2023 Sep 26]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33123968\/."},{"key":"709_CR32","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1200\/JCO.24.00144","volume":"42","author":"Y-S Lu","year":"2024","unstructured":"Lu Y-S, Mahidin EIBM, Azim H, Eralp Y, Yap YS, Im S-A, et al. Final results of RIGHT choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer. J Clin Oncol. 2024;42:2812\u201321.","journal-title":"J Clin Oncol"},{"key":"709_CR33","unstructured":"Safety and feasibility of CDK4\/6 inhibitors treatment combined with radiotherapy in patients with HR-positive\/HER2-negative breast cancer. A systematic review and meta-analysis\u2014PubMed [Internet]. [cited 2023 Sep 26]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37536378\/."},{"key":"709_CR34","unstructured":"CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis\u2014PubMed [Internet]. [cited 2023 Sep 26]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33233970\/."},{"key":"709_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102086","volume":"90","author":"A Desnoyers","year":"2020","unstructured":"Desnoyers A, Nadler MB, Kumar V, Saleh R, Amir E. Comparison of treatment-related adverse events of different cyclin-dependent kinase 4\/6 inhibitors in metastatic breast cancer: a network meta-analysis. Cancer Treat Rev. 2020;90: 102086.","journal-title":"Cancer Treat Rev"},{"key":"709_CR36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.breast.2022.02.011","volume":"62","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Ma Z, Sun X, Feng X, An Z. Interstitial lung disease in patients treated with cyclin-dependent kinase 4\/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Breast. 2022;62:162\u20139.","journal-title":"Breast"},{"key":"709_CR37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-020-05783-3","volume":"183","author":"KZ Thein","year":"2020","unstructured":"Thein KZ, Htut TW, Ball S, Swarup S, Sultan A, Oo TH. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4\/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2020;183:479\u201387.","journal-title":"Breast Cancer Res Treat"},{"key":"709_CR38","doi-asserted-by":"crossref","unstructured":"Paris S, Tarantini L, Navazio A, Faggiano P. Cardio-oncology: the new frontier of clinical and preventive cardiology. Monaldi Arch Chest Dis. 2020;90.","DOI":"10.4081\/monaldi.2020.1348"},{"key":"709_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31:171\u201390.","journal-title":"Ann Oncol"},{"key":"709_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2478\/fco-2019-0007","volume":"10","author":"TC Vasiliki","year":"2019","unstructured":"Vasiliki TC, Aristeidis GT, Christos AK, Timotheadou ET. The pharmacological profile of cyclin-dependent kinase (CDK) 4\/6 inhibitors: clinical management of toxicity and drug interactions related to CDK 4\/6 inhibitor-based treatment in advanced\/metastatic breast cancer. Forum Clin Oncol. 2019;10:2\u201314.","journal-title":"Forum Clin Oncol"},{"key":"709_CR41","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.clml.2015.02.021","volume":"15","author":"RD Cassaday","year":"2015","unstructured":"Cassaday RD, Goy A, Advani S, Chawla P, Nachankar R, Gandhi M, et al. A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276\u201300, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2015;15:392\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"709_CR42","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ajh.2008.369","volume":"22","author":"E Rosell\u00f3-Llet\u00ed","year":"2009","unstructured":"Rosell\u00f3-Llet\u00ed E, Rivera M, Mart\u00ednez-Dolz L, Gonz\u00e1lez Juanatey JR, Cort\u00e9s R, Jord\u00e1n A, et al. Inflammatory activation and left ventricular mass in essential hypertension. Am J Hypertens. 2009;22:444\u201350.","journal-title":"Am J Hypertens"},{"key":"709_CR43","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1161\/01.RES.0000130526.20854.fa","volume":"94","author":"M Nian","year":"2004","unstructured":"Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94:1543\u201353.","journal-title":"Circ Res"},{"key":"709_CR44","unstructured":"Inflammatory markers are associated with left ventricular hypertrophy and diastolic dysfunction in a population-based sample of elderly men and women\u2014PubMed [Internet]. [cited 2024 Nov 4]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22237633\/."},{"key":"709_CR45","unstructured":"Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety\u2014PubMed [Internet]. [cited 2023 Sep 24]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16507548\/."},{"key":"709_CR46","unstructured":"Molecular mechanism of G1 arrest and cellular senescence induced by LEE011, a novel CDK4\/CDK6 inhibitor, in leukemia cells\u2014PubMed [Internet]. [cited 2023 Sep 24]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28286417\/."},{"key":"709_CR47","unstructured":"Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors\u2014PubMed [Internet]. [cited 2023 Sep 24]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33270827\/."},{"key":"709_CR48","unstructured":"Adverse cardiovascular events associated with cyclin-dependent kinase 4\/6 inhibitors in patients with metastatic breast cancer\u2014PubMed [Internet]. [cited 2024 Feb 1]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37301767\/."},{"key":"709_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.638895","volume":"8","author":"C Papageorgiou","year":"2021","unstructured":"Papageorgiou C, Zagouri F, Tampakis K, Georgakopoulou R, Manios E, Kafouris P, et al. Vascular inflammation and cardiovascular burden in metastatic breast cancer female patients receiving hormonal treatment and CDK 4\/6 inhibitors or everolimus. Front Cardiovasc Med. 2021;8: 638895.","journal-title":"Front Cardiovasc Med."},{"key":"709_CR50","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40259-019-00382-1","volume":"33","author":"M Santoni","year":"2019","unstructured":"Santoni M, Occhipinti G, Romagnoli E, Miccini F, Scoccia L, Giulietti M, et al. Different cardiotoxicity of palbociclib and ribociclib in breast cancer: gene expression and pharmacological data analyses, biological basis, and therapeutic implications. BioDrugs. 2019;33:613\u201320.","journal-title":"BioDrugs"},{"key":"709_CR51","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jbi.2016.02.009","volume":"60","author":"H Ibrahim","year":"2016","unstructured":"Ibrahim H, Saad A, Abdo A, Sharaf EA. Mining association patterns of drug-interactions using post marketing FDA\u2019s spontaneous reporting data. J Biomed Inform. 2016;60:294\u2013308.","journal-title":"J Biomed Inform"},{"key":"709_CR52","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/jcpt.13598","volume":"47","author":"Q Yu","year":"2022","unstructured":"Yu Q, Xu Y, Yu E, Zheng Z. Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: a systematic review and meta-analysis. J Clin Pharm Ther. 2022;47:575\u201387.","journal-title":"J Clin Pharm Ther"},{"key":"709_CR53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1253\/circj.CJ-13-0266","volume":"78","author":"T-L Yang","year":"2014","unstructured":"Yang T-L, Wu T-C, Huang C-C, Huang P-H, Chung C-M, Lin S-J, et al. Association of tamoxifen use and reduced cardiovascular events among asian females with breast cancer. Circ J. 2014;78:135\u201340.","journal-title":"Circ J"},{"key":"709_CR54","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","volume":"24","author":"V Guarneri","year":"2006","unstructured":"Guarneri V, Lenihan DJ, Valero V, Durand J-B, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006;24:4107\u201315.","journal-title":"J Clin Oncol"},{"key":"709_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"709_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00709-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00709-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00709-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T13:03:22Z","timestamp":1745327002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00709-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["709"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00709-6","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"23 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by two funding sources: 1. The National Natural Science Foundation of China (Grant Number:\u00a082160859), and 2. The Kunlun Talents Program of Qinghai Province for high-end innovative and entrepreneurial talents. The funders had no role in the study design, nor in the collection, analysis, interpretation of data, writing of the report, or the decision to submit the article for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"C.Z., G.S., S.L., F.M., H.L., Y.T., Y.X.L., Z.Li, Z.Z., T.Q., Z.Liu, Y.Z., S.H., F.Z., F.K., and J.Z. declare that they have no potential conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"C.Z., S.L. contributed to search studies; C.Z., F.K., H.L., Y.T., and Y.X.L. contributed to data extraction; C.Z., G.S., J.Z contributed to finishing the draft. All authors were involved in the revision and approval of the manuscript. C.Z., Y.X.L., F.M., and J.Z. carried out the study conception and design; Z.Li., Z.Z., T.Q., and Z.Liu carried out acquisition, analysis, or interpretation of data; C.Z. and J.Z. drafted the manuscript; All authors carried out critical revision of the manuscript for important intellectual content; Z.Y., S.H., and F.Z. carried out statistical analysis; S.L., F.M., F.Z., and Y.Z. carried out administrative, technical, or material support; J.Z. supervised the study. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The search strategy and all the data used to generate the results presented in this systematic review can be found in the supplementary material.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}